Characterization of tolazamide binding with glycated and normal human serum albumin by using high-performance affinity chromatography

Pingyang Tao, Zhao Li, Ashley G. Woolfork, David S Hage

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Sulfonylurea drugs are antidiabetic drugs that are utilized in the treatment of type II diabetes and often have significant binding with human serum albumin (HSA). Immobilized samples of normal or glycated HSA in affinity microcolumns were used to investigate interactions of these proteins with the sulfonylurea drug tolazamide. HPLC and frontal analysis were used to first examine the overall binding of this drug with these samples of HSA. It was found that tolazamide had two general classes of binding sites (i.e., high and low affinity) for normal and glycated HSA. The higher affinity sites had binding constants of around 4.3–6.0 × 104 M−1 for these interactions at pH 7.4 and 37 °C, while the lower affinity sites had binding strengths of 4.9–9.1 × 103 M−1. Zonal competition studies between tolazamide and probes for Sudlow sites I and II on HSA were also performed and used to provide site-specific affinities for tolazamide at these sites. A decrease of 22% in affinity was observed for tolazamide at Sudlow site I and an increase up to 58% was seen at Sudlow site II when comparing glycated HSA with normal HSA. These observed changes were compared to those of other first-generation sulfonylurea drugs, providing information on how glycation can alter the total and local binding strength of tolazamide and related compounds with HSA under levels of glycation seen in patients with diabetes.

Original languageEnglish (US)
Pages (from-to)273-280
Number of pages8
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume166
DOIs
StatePublished - Mar 20 2019

Fingerprint

Tolazamide
Affinity chromatography
Affinity Chromatography
Serum Albumin
Binding Sites
Binding sites
Medical problems
Pharmaceutical Preparations
Hypoglycemic Agents
Type 2 Diabetes Mellitus
High Pressure Liquid Chromatography

Keywords

  • Affinity microcolumn
  • Drug-protein binding
  • Glycation
  • Human serum albumin
  • Tolazamide

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Cite this

Characterization of tolazamide binding with glycated and normal human serum albumin by using high-performance affinity chromatography. / Tao, Pingyang; Li, Zhao; Woolfork, Ashley G.; Hage, David S.

In: Journal of Pharmaceutical and Biomedical Analysis, Vol. 166, 20.03.2019, p. 273-280.

Research output: Contribution to journalArticle

@article{04c07f7f8854413cab297e9e6ee98a12,
title = "Characterization of tolazamide binding with glycated and normal human serum albumin by using high-performance affinity chromatography",
abstract = "Sulfonylurea drugs are antidiabetic drugs that are utilized in the treatment of type II diabetes and often have significant binding with human serum albumin (HSA). Immobilized samples of normal or glycated HSA in affinity microcolumns were used to investigate interactions of these proteins with the sulfonylurea drug tolazamide. HPLC and frontal analysis were used to first examine the overall binding of this drug with these samples of HSA. It was found that tolazamide had two general classes of binding sites (i.e., high and low affinity) for normal and glycated HSA. The higher affinity sites had binding constants of around 4.3–6.0 × 104 M−1 for these interactions at pH 7.4 and 37 °C, while the lower affinity sites had binding strengths of 4.9–9.1 × 103 M−1. Zonal competition studies between tolazamide and probes for Sudlow sites I and II on HSA were also performed and used to provide site-specific affinities for tolazamide at these sites. A decrease of 22{\%} in affinity was observed for tolazamide at Sudlow site I and an increase up to 58{\%} was seen at Sudlow site II when comparing glycated HSA with normal HSA. These observed changes were compared to those of other first-generation sulfonylurea drugs, providing information on how glycation can alter the total and local binding strength of tolazamide and related compounds with HSA under levels of glycation seen in patients with diabetes.",
keywords = "Affinity microcolumn, Drug-protein binding, Glycation, Human serum albumin, Tolazamide",
author = "Pingyang Tao and Zhao Li and Woolfork, {Ashley G.} and Hage, {David S}",
year = "2019",
month = "3",
day = "20",
doi = "10.1016/j.jpba.2019.01.025",
language = "English (US)",
volume = "166",
pages = "273--280",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

TY - JOUR

T1 - Characterization of tolazamide binding with glycated and normal human serum albumin by using high-performance affinity chromatography

AU - Tao, Pingyang

AU - Li, Zhao

AU - Woolfork, Ashley G.

AU - Hage, David S

PY - 2019/3/20

Y1 - 2019/3/20

N2 - Sulfonylurea drugs are antidiabetic drugs that are utilized in the treatment of type II diabetes and often have significant binding with human serum albumin (HSA). Immobilized samples of normal or glycated HSA in affinity microcolumns were used to investigate interactions of these proteins with the sulfonylurea drug tolazamide. HPLC and frontal analysis were used to first examine the overall binding of this drug with these samples of HSA. It was found that tolazamide had two general classes of binding sites (i.e., high and low affinity) for normal and glycated HSA. The higher affinity sites had binding constants of around 4.3–6.0 × 104 M−1 for these interactions at pH 7.4 and 37 °C, while the lower affinity sites had binding strengths of 4.9–9.1 × 103 M−1. Zonal competition studies between tolazamide and probes for Sudlow sites I and II on HSA were also performed and used to provide site-specific affinities for tolazamide at these sites. A decrease of 22% in affinity was observed for tolazamide at Sudlow site I and an increase up to 58% was seen at Sudlow site II when comparing glycated HSA with normal HSA. These observed changes were compared to those of other first-generation sulfonylurea drugs, providing information on how glycation can alter the total and local binding strength of tolazamide and related compounds with HSA under levels of glycation seen in patients with diabetes.

AB - Sulfonylurea drugs are antidiabetic drugs that are utilized in the treatment of type II diabetes and often have significant binding with human serum albumin (HSA). Immobilized samples of normal or glycated HSA in affinity microcolumns were used to investigate interactions of these proteins with the sulfonylurea drug tolazamide. HPLC and frontal analysis were used to first examine the overall binding of this drug with these samples of HSA. It was found that tolazamide had two general classes of binding sites (i.e., high and low affinity) for normal and glycated HSA. The higher affinity sites had binding constants of around 4.3–6.0 × 104 M−1 for these interactions at pH 7.4 and 37 °C, while the lower affinity sites had binding strengths of 4.9–9.1 × 103 M−1. Zonal competition studies between tolazamide and probes for Sudlow sites I and II on HSA were also performed and used to provide site-specific affinities for tolazamide at these sites. A decrease of 22% in affinity was observed for tolazamide at Sudlow site I and an increase up to 58% was seen at Sudlow site II when comparing glycated HSA with normal HSA. These observed changes were compared to those of other first-generation sulfonylurea drugs, providing information on how glycation can alter the total and local binding strength of tolazamide and related compounds with HSA under levels of glycation seen in patients with diabetes.

KW - Affinity microcolumn

KW - Drug-protein binding

KW - Glycation

KW - Human serum albumin

KW - Tolazamide

UR - http://www.scopus.com/inward/record.url?scp=85060247086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060247086&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2019.01.025

DO - 10.1016/j.jpba.2019.01.025

M3 - Article

VL - 166

SP - 273

EP - 280

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -